Status:
COMPLETED
Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.
Lead Sponsor:
Pfizer
Conditions:
Ocular Hypertension
Glaucoma, Open-Angle
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.
Eligibility Criteria
Inclusion
- Unilateral or bilateral open-angle glaucoma, exfoliative glaucoma, pigmentary glaucoma or ocular hypertension
- IOP of \> 21 mm Hg on current treatment
Exclusion
- Any previous or current treatment with latanoprost or other prostaglandin analogues
Key Trial Info
Start Date :
February 1 2002
Trial Type :
INTERVENTIONAL
End Date :
April 1 2006
Estimated Enrollment :
329 Patients enrolled
Trial Details
Trial ID
NCT00140062
Start Date
February 1 2002
End Date
April 1 2006
Last Update
April 7 2008
Active Locations (27)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Ekenäs, Finland
2
Pfizer Investigational Site
Helsinki, Finland, 00100
3
Pfizer Investigational Site
Helsinki, Finland, 00700
4
Pfizer Investigational Site
Kuopio, Finland, 70100